A recent blog of mine described how unethical and illegal drug company activities have driven the prescription of toxic antipsychotic drugs to children. Now the "success" of this campaign has been documented in the Archives of General Psychiatry. In a comparison between the years 1993-1998 and 2005-2009, prescriptions of antipsychotic drugs for per 100 children (0-13 years old) rose from 0.24 to 1.83. That's more than a sevenfold increase. Given that most of prescriptions are for the older children in this age range, the rate would be substantially higher among preteens and 13-year-olds. For adolescents (14-20 years old) the increase was nearly fivefold.
This report comes out at a poignant time for me. Right now one of my patients, a 7-year-old boy I will called "Joey," has just returned from being psychiatrically hospitalized because he could not be withdrawn from the antipsychotic drug Risperdal as an outpatient. The family came to me for help in getting this child off the psychiatric drugs he'd been prescribed by another psychiatrist. A basically sweet and lovable boy, the withdrawal was such an agony for him that he became uncontrollably violent. Meanwhile, he already suffers from tardive dyskinesia, a persistent and commonly permanent movement disorder from antipsychotic drug exposure that causes abnormal movements, including deforming facial grimaces and disabling involuntary movements of the torso and limbs.
Joey is also a victim of precocious puberty, almost certainly caused by the Risperdal. Although largely ignored in the scientific literature, according to Philadelphia attorney Steve Sheller, many cases of Risperdal-induced premature puberty in boys are showing up as legal cases.
My patient Joey became dangerously violent for the first time after exposure to antipsychotic medication and then became even more violent during withdrawal. You can witness similar reactions in stunning footage from an ABC News documentary about U.S. foster children prescribed large quantities of psychiatric drugs, including Brooke, also age 7, who had been exposed to the drugs since the age of 4. When she was finally taken to a psychiatrist who recognized what was happening to her, the doctor observed, "The first thing we've got to think about: Is the medicine causing this? ... There always has to be a high index of suspicion when we're using these agents."
Unlike the escalation in stimulant drugs prescribed to children for attention deficit hyperactivity disorder (ADHD), which is led by pediatricians and family doctors, psychiatrists are doing most of the prescribing of antipsychotic drugs to children. As reported earlier, the drugging of children with antipsychotic drugs is a direct result of off-label (unapproved) uses promoted by the drug companies in cooperation with unscrupulous psychiatrists and researchers in leadership roles in the profession. The new Archives of General Psychiatry study confirms that most of the prescriptions of antipsychotic drugs to children have indeed been off-label for disruptive behavioral disorders. Instead of helping parents and teachers to improve their methods of disciplining children, psychiatrists are suppressing the overall mental life and behavior of these youngsters with antipsychotic drugs.
A courageous psychologist, Jerome Kagan, was recently interviewed by Spiegel about the epidemic of "mental illness" in children:
SPIEGEL: Experts speak of 5.4 million American children who display the symptoms typical of ADHD. Are you saying that this mental disorder is just an invention?
Kagan: That's correct; it is an invention. Every child who's not doing well in school is sent to see a pediatrician, and the pediatrician says: "It's ADHD; here's Ritalin." ... The problem is, if a drug is available to doctors, they'll make the corresponding diagnosis.
SPIEGEL: So the alleged health crisis among children is actually nothing but a bugaboo?
Kagan: We could get philosophical and ask ourselves: "What does mental illness mean?" If you do interviews with children and adolescents aged 12 to 19, then 40 percent can be categorized as anxious or depressed. But if you take a closer look and ask how many of them are seriously impaired by this, the number shrinks to 8 percent. Describing every child who is depressed or anxious as being mentally ill is ridiculous. Adolescents are anxious, that's normal. They don't know what college to go to. Their boyfriend or girlfriend just stood them up. Being sad or anxious is just as much a part of life as anger or sexual frustration.
SPIEGEL: What does it mean if millions of American children are wrongly being declared mentally ill?
Kagan: Well, most of all, it means more money for the pharmaceutical industry and more money for psychiatrists and people doing research.
SPIEGEL: And what does it mean for the children concerned?
Kagan: For them, it is a sign that something is wrong with them -- and that can be debilitating. I'm not the only psychologist to say this. But we're up against an enormously powerful alliance: pharmaceutical companies that are making billions, and a profession that is self-interested.
As Dr. Kagan confirms, children suffer psychologically and developmentally from being wrongly diagnosed "mentally ill." There are also extraordinary medical risks from exposure to antipsychotics. The Archives of General Psychiatry report mentions that these drugs may cause increased blood sugar, diabetes, increased lipids (cholesterol), and obesity. It does not mention that these adverse reactions greatly elevate the risk of later heart disease, especially since these drugs also compromise cardiac function.
The study also neglects to mention tardive dyskinesia, neuroleptic malignant syndrome (a potential fatal disease that mimics a viral brain disease), and a variety of other hazards caused by these drugs in children as well as adults. It does not mention that studies done on schizophrenic patients being treated with these drugs -- here, here and here, for example -- continue to indicate that antipsychotic drugs are toxic to brain cells, and that they are associated with shrinkage of the brain.
Documenting the rising trend of antipsychotic prescriptions for children and youth is vital, but why do the authors of the new study call for more clinical trials to test the safety and efficacy of these drugs in children? Why don't they call for a moratorium on the off-label psychiatric drugging of children and youth with antipsychotic drugs? The answer may lie in the authors' many financial ties to multiple international drug companies.
In the financial disclosures section at the end of this report, a rogues gallery of pharmaceutical companies are listed including Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Janssen/Johnson & Johnson, Pfizer, Schering-Plough, and more.
As I describe in my new book, Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients and Their Families, health professionals must stop the psychiatric drugging of children and focus on developing facilities and approaches for helping children as well as adults to withdraw from these drugs as safely as possible. An epidemic of brain damage and other bodily harms could be stopped by curtailing the drugging of children and by encouraging their safe withdrawal from these hazardous chemical intrusions into their brains, minds, and lives.
Meanwhile, there is no mystery about what children need from us. They need more of us. Whether the child is having difficulty focusing in school or behaving at home, whether the child is having difficulty socializing or communicating, and whether the child is given no psychiatric diagnosis or a serious diagnosis -- all children need caring, informed, disciplined and dedicated attention from the adults in their lives. As adults, we need to retake responsibility for raising and educating our children.
Peter R. Breggin, MD is a psychiatrist in private practice in Ithaca, New York, and the author of dozens of scientific articles and more than twenty books. His most recent book is Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients and Their Families. The first half of the book describes a broad array of adverse effects that should lead to drug reduction or withdrawal, and the second half describes a person-centered team approach to accomplishing drug withdrawal. Dr. Breggin's website is www.breggin.com.
For more by Dr. Peter Breggin, click here.
For more healthy living health news, click here.